Why This Matters
Prescription drug prices remain a major strain for many Americans, especially people managing chronic illnesses without reliable insurance coverage. The White House-backed TrumpRx website aims to lower some of those costs by negotiating steep discounts with large pharmaceutical companies.
AbbVie and Genentech’s decision to add widely used drugs to the platform extends those discounts to more patients who now pay full list prices. While the program is limited to people who are uninsured or whose plans do not cover these medicines, it signals a broader push to make high-cost drugs more affordable.
This move also fits into a larger policy debate over how far the federal government should go in negotiating or regulating drug prices. What happens with TrumpRx and related plans could shape future efforts by Congress or administrations to address prescription costs more broadly.
Key Facts and Quotes
According to a report by CBS News, AbbVie and Genentech will become the 10th and 11th pharmaceutical companies to sell medicines at reduced prices on TrumpRx, the White House’s discount prescription website. The additions are expected to begin as soon as Monday, bringing the total number of discounted drugs on the site to more than 61, up from roughly 40 at launch in February.
AbbVie, a major American drugmaker, will offer Humira on TrumpRx at what a White House official described as an 86 percent discount. Humira (adalimumab) is used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. For uninsured patients, the price of a Humira Pen can exceed 6,900 dollars, but TrumpRx coupons will bring it down to about 950 dollars, the official told CBS News.
The Trump administration has tied these discounts to its “most-favored-nation” approach, under which companies agree to sell medicines to uninsured U.S. consumers at prices comparable to those in other countries. A White House official said the administration is also working to fold these deals into its proposed “Great Healthcare Plan,” with the goal of allowing people on government insurance programs to use copays for TrumpRx drugs, though Congress has not acted on that plan.
Genentech, another large U.S.-based pharmaceutical company, will reduce the price of Xofluza, a single-dose pill used to treat and prevent the flu. Under a December agreement, Xofluza will cost about $50 on TrumpRx, down from about $ 168, according to the White House. Amgen, which already participates in TrumpRx, will expand its offerings to include arthritis drug Enbrel and plaque psoriasis treatment Otezla.
What It Means for You
For now, TrumpRx discounts apply only to people who are uninsured or whose insurance does not cover the specific drugs, leaving them to pay full list prices out of pocket. Those with private or government insurance typically face lower costs through their plans and cannot yet use TrumpRx discounts in combination with existing coverage.
Going forward, the key questions are whether more drugmakers will join the program, whether Congress will take up the proposed Great Healthcare Plan, and how these discounts will interact with broader efforts to control prescription drug prices. Patients who rely on high-cost medicines may want to watch which drugs are added to TrumpRx and whether eligibility rules change.
How do you think government programs and private companies should share responsibility for making essential prescription drugs more affordable?
Sources
CBS News report by Olivia Rinaldi on TrumpRx discounts, published April 6, 2026; Public White House statements and fact sheets on prescription drug pricing initiatives and most-favored-nation policies, various dates 2018-2020.
